Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Generics brief legal “logic” on Hayashi :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
HinduKush Member Profile
Member Level 
Followed By 24
Posts 1,041
Boards Moderated 0
Alias Born 07/26/19
160x600 placeholder
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderat... GlobeNewswire Inc. - 10/23/2020 7:00:10 AM
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 GlobeNewswire Inc. - 10/19/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interv... GlobeNewswire Inc. - 10/15/2020 4:30:10 PM
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EA... GlobeNewswire Inc. - 10/5/2020 7:00:10 AM
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/9/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:21:33 PM
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire Inc. - 9/3/2020 10:51:52 AM
Traders News Source Issues "Potential Home Run" New Research Report InvestorsHub NewsWire - 9/3/2020 9:00:00 AM
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Ri... GlobeNewswire Inc. - 9/1/2020 4:30:10 PM
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ES... GlobeNewswire Inc. - 8/29/2020 3:13:10 AM
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented... GlobeNewswire Inc. - 8/17/2020 7:00:10 AM
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
HinduKush Member Level  Tuesday, 06/30/20 10:48:39 AM
Re: None
Post # of 306881 
Generics brief legal “logic” on Hayashi :
1. There must have been ONE patient in Hayashi with TG> 500 mg/dl
2. This study was for the most part < 500 mg/dl. We contend that POSA 2008 expected on the basis of Mori and Kurabayashi that EPA reduces or does not elevate LDL in this < 500mg/dl population.
3. 200-500 mg/dl TG is still < = 500mg/dl. Ergo, If 2 is true, then a single patient at 500mg/dl would also have been expected to not elevate LDL with EPA. Which means that what we say about LDL being not expected to go up with EPA holds true for any range that starts or ends at the value 500 - either plus or minus e.g 150-500, 500-1500 mg/dl or 500- 100,000,000 mg/dl, because 500 is 500 is 500 plus or 500 minus. Q. E. D.

This works apparently in the legal system!

Ok so

1. I have run a 5K last year in Las Vegas and my wife barely dragged my sorry ass over the finishing line.
2. Many people run the 5K then the 10K then the full marathon on consecutive days and have done so for many years before I arrived on the scene of competitive running.
3. Given that I can put one foot in front of the other to complete a 5K, and since a 5 K is encompassed in completing a 10K I should be able to do a 10 K, and since a 10 K is no different likewise from a marathon it follows I should have every expectation of running all 3 races and not end up being coded at the finish line... Based on the prior art and my prima facie obviousness evaluation and after weighing and discounting all secondary objective indicia from my wife who points out skeptically that a man who could not tie his shoe laces yesterday without losing his breath.. and despite the long felt unmet need for regular exercise training and despite the commercial failure in obtaining industrial sponsorship for my running career; I will now bench order that the prima facie evidence of prior art is that its overwhelmingly obvious I could do all three races and should forthwith enroll for all 3 (notwithstanding the lack of insurance coverage for suicide)....

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences